Novo Nordisk plans cost cuts amid slower Wegovy growth outlook

3 hours ago 1

Healthcare

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic versions of its obesity drug Wegovy, with slower growth expected for its treatments in the second half of

Recommended For You

More Trending News

Read Entire Article

Novo Nordisk plans cost cuts amid slower Wegovy growth outlook

Recommended For You

More Trending News

Related

Vishay Intertechnology Non-GAAP EPS of -$0.07 misses by $0.0...

Griffon declares $0.18 dividend

Avista misses top-line and bottom-line estimates; reaffirms ...

Uber sets $20B stock buyback plan

Vertex beats bottom-line estimates; initiates Q3 and updates...

Seres Therapeutics GAAP EPS of -$2.27 beats by $0.22

Steel Partners Holdings 6% Pfd Partnership Unit Series A dec...

Who’s on Trump’s shortlist for Jerome Powell’s replacement a...

Telesat GAAP EPS of $1.38, revenue of $106M

Bentley Systems beats top-line and bottom-line estimates; on...

Pershing Square Holdings declares $0.1646 dividend

Acacia Research Non-GAAP EPS of -$0.06, revenue of $51.2M

Astec Non-GAAP EPS of $0.88 beats by $0.32, revenue of $330....

Arvinas GAAP EPS of -$0.84 beats by $0.10, revenue of $22.4M...

Restaurant check: McDonald's rallies after returning to posi...

Nuveen Churchill Direct Lending Corp. GAAP EPS of $0.46 in-l...

Dayforce Non-GAAP EPS of $0.61 beats by $0.08, revenue of $4...

MarketAxess Non-GAAP EPS of $2.00 beats by $0.03, revenue of...

New York Times Non-GAAP EPS of $0.58 beats by $0.07, revenue...

Starbucks’ stock is being pummelled by Trump’s coffee tariff...

Trending

Popular

اعزام اورژانس هرمزگان به مرز شلمچه

این یک داستان واقعی از دو قهرمان در آذربایجان شرقى در نبرد ب...